Navigation Links
NimbleGen to discontinue IPO after Roche's $272.5 million acquisition

xciting" development for the state's biotechnology industry, noting that state officials have been trying to attract a global pharmaceutical company.

Leonhart cited the state's courting of Abbott Labs, which has acquired 500 acres of land in the Kenosha County communities of Pleasant Prairie and Bristol, but has yet to officially announce whether i......

Full article >>>
'"/>

Source:wistechnology.com By Joe Vanden Plas 06/19/07


Page: 1 2 3 4

Related biology technology :

1. NimbleGen researcher to lead $415K DNA project
2. IPO-bound NimbleGen traveling in fast company
3. Madison biotech NimbleGen files for IPO; one of states best-funded firms
4. Genomics researcher Hood joins NimbleGen board
5. NimbleGen partners with UK biotech firm
6. NimbleGen extends research market reach
7. NimbleGen microarrays speed genetic findings
8. NimbleGen names CFO with capital-raising past
9. NimbleGen partners with leading researchers
10. NimbleGen closes $8.2m venture round, bringing total to $50m
11. NimbleGen Systems CGS technique helps identify stomach bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: NimbleGen discontinue IPO after Roche million acquisition

(Date:11/20/2008)...echnology sector is $45.8 billion, 180,007 jobs ,...Newswire-USNewswire/ -- North Carolina has investe...ogy enterprise during the past 10 years, and the a...ng to data released today at the North Carolina Bi...ident and CEO of the Biotechnology Center, and lea...
(Date:11/20/2008)...swire-FirstCall/ -- Neurocrine Biosciences, Inc.,...n, President and Chief,Executive Officer of Neuro...Annual Piper Jaffray Health Care Conference in New...ion takes place Tuesday, December 2,2008 at 1:30...PT). The,presentation will be simultaneously webc...
(Date:11/20/2008)...Newswire/ -- KansasBio announced today a,bioscien...gion,s human,health-care-related bioscience compa...nuum. Called the National Drug Development Acceler...mpanies across Kansas and the Kansas,City metropo...ferred resources,for drug development. , K...
(Date:11/20/2008)... MicroPhage, Inc., http://www.mic... latest round,of financing, which brings total ca...ound were a combination of existing and new invest...vestors. , MicroPhage will apply proceeds o...unch preparation of their initial diagnostic produ...
Breaking Biology Technology:North Carolina's Biotechnology Investment Tops Billion-Dollar Mark; Battelle Study Quantifies Economic Dividends and Jobs 2North Carolina's Biotechnology Investment Tops Billion-Dollar Mark; Battelle Study Quantifies Economic Dividends and Jobs 3North Carolina's Biotechnology Investment Tops Billion-Dollar Mark; Battelle Study Quantifies Economic Dividends and Jobs 4North Carolina's Biotechnology Investment Tops Billion-Dollar Mark; Battelle Study Quantifies Economic Dividends and Jobs 5National Drug Development Accelerator Launched 2MicroPhage Closes Latest Financing 2
...Gen Systems , a manufacturer of gene chips for pha...ward an initial public offering of stock following...d based pharmaceutical giant. , ,NimbleGen had sou... terms of a definitive agreement announced by the ...he privately held NimbleGen from shareholders for ...
...effort to revive Legislative support for his biofu...an skeptics, suggesting that GOP lawmakers are pay... their backs on state farmers, manufacturers, and ...ks to date, said every county in the state has mor... benefit from a the bio-industry. , ,This should ...
...hneider, a director for the Green Bay-based transp...ed to the board of TrafficCast International , a ...,At Schneider National, Schneider is responsible f...an $3.5 billion in annual revenue. , ,Schneider is...y in transportation logistics, so there is synergy...
... controls is clearly in the hands of people. While...ly gained momentum in an effort to reduce testing ...majority of entity-wide controls rely upon people.... the essence of entity-wide controls, is a company...n cost efficiencies. Competent people working with...
Other Biology Technology:NimbleGen to discontinue IPO after Roche's $272.5 million acquisition 2NimbleGen to discontinue IPO after Roche's $272.5 million acquisition 3NimbleGen to discontinue IPO after Roche's $272.5 million acquisition 4Technology helps but the best way to reduce Sarbox cost is with people 2Technology helps but the best way to reduce Sarbox cost is with people 3Technology helps but the best way to reduce Sarbox cost is with people 4
(Date:11/21/2008)... , , , , , , , , ... , Graduate student Sue Lynn Lau participated ...pleting a PhD at Garvan Institute of Medical Resea...her... , , Click here for more i..., , , , , , , , ...
(Date:11/21/2008)...nd ecological sustainability of biofuels and the i...l and South America will take place on Friday, Dec...Biofuels and Neotropical Forests: Trends, Implicat...e Environmental and Leadership Training Initiative...ation, both joint programs of the Yale School of F...
(Date:11/21/2008)...ttacks and strokes are treated quite separately fr... but now turn out to involve some of the same crit...rn provides clues to more effective therapies for ...res researchers in these distinct fields to come t...n between these two groups at a recent workshop or...
(Date:11/21/2008)...h Americans are becoming increasingly aware of tox...cts like bisphenol A in some baby bottles and lead...l household products with personal chemical exposu...o research from the December issue of the Journal...sociologist Phil Brown is a co-author of the study...
Breaking Biology News(10 mins):The 2009 AAAS/Science dance contest winners are announced 2The 2009 AAAS/Science dance contest winners are announced 3The 2009 AAAS/Science dance contest winners are announced 4The 2009 AAAS/Science dance contest winners are announced 5The 2009 AAAS/Science dance contest winners are announced 6The 2009 AAAS/Science dance contest winners are announced 7Conference to explore sustainability of biofuels 2Mechanisms of cardiovascular disease and cancer give clues to new therapies 2Mechanisms of cardiovascular disease and cancer give clues to new therapies 3Household exposure to toxic chemicals lurks unrecognized, researchers find 2Household exposure to toxic chemicals lurks unrecognized, researchers find 3Nephros Exhibiting at Denver Colorado APIC Conference June 15th 19th 21012 1Nephros Exhibiting at Denver Colorado APIC Conference June 15th 19th 21012 2Nephros Exhibiting at Denver Colorado APIC Conference June 15th 19th 21012 3Nephros Exhibiting at Denver Colorado APIC Conference June 15th 19th 21012 4Resveratrol 3A Thousands of Bottles of Wine High Dose Pills Not Required 3B Mega doses May Induce Side Effects 21007 1Resveratrol 3A Thousands of Bottles of Wine High Dose Pills Not Required 3B Mega doses May Induce Side Effects 21007 2Resveratrol 3A Thousands of Bottles of Wine High Dose Pills Not Required 3B Mega doses May Induce Side Effects 21007 3Resveratrol 3A Thousands of Bottles of Wine High Dose Pills Not Required 3B Mega doses May Induce Side Effects 21007 4Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late Stage Development of Voreloxin 28Formerly SNS 595 29 5787 1Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late Stage Development of Voreloxin 28Formerly SNS 595 29 5787 2Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late Stage Development of Voreloxin 28Formerly SNS 595 29 5787 3Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late Stage Development of Voreloxin 28Formerly SNS 595 29 5787 4Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late Stage Development of Voreloxin 28Formerly SNS 595 29 5787 5Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late Stage Development of Voreloxin 28Formerly SNS 595 29 5787 6Family history of colorectal cancer linked with reduced risk of cancer recurrence 21002 1Family history of colorectal cancer linked with reduced risk of cancer recurrence 21002 2Family history of colorectal cancer linked with reduced risk of cancer recurrence 21002 3
... the Endangered Species Act in 1973, over 1,300 en... States and its territories. In the forthcoming is...years of endangered plant and animal status trends...ected, and the amount of money spent on their cons... Overall, about half of species protected are no l...
...quest for viral-based therapies for cancer , Rese...inue to make strides in their work to develop the ... for cancer. Two papers about promising research ...e, published today in the journals Cancer Research...iences (PNAS), bring us significantly closer to th...
...the word “citrus?conjures up images of oranges, gr...r blood oranges, if you’re a true connoisseur of f...ueger, the genus Citrus includes at least 16 speci...lesser-known, peelable oddities like pummelos, tri...ith the ARS National Clonal Germplasm Repository f...
...cer drugs differed dramatically in a laboratory te...overactive growth signal in lung cancer cells, rep...r Cancer Institute. , Although both drugs killed c...ermal growth factor receptor) molecule, only gefit...a mutated EGFR molecule. The monoclonal antibody d...
Other Biology News:Columbia scientists develop cancer terminator viruses 2Columbia scientists develop cancer terminator viruses 3From a Few Wild Ancestors, a Citrus Cornucopia 2From a Few Wild Ancestors, a Citrus Cornucopia 3From a Few Wild Ancestors, a Citrus Cornucopia 4Two designer drugs hit same lung cancer target, but only one is effective 2
Anti-Human Factor XI Purified (Polyclonal) (sheep IgG)
Formulation: 10mM PBS/500 mM NaCl, 0.09% NaN3, pH 7.2
Rad51B
Goat polyclonal to Dysadherin ( Abpromise for all tested applications). entrezGeneID: 53827
Biology Products: